10 results
The primary objective is:1. To investigate whether high frequency low dosage IVIg treatment is more effective than low frequency high dosage as maintenance treatment for CIDP. Secondary objectives are:2. To investigate whether high frequency low…
To investigate that in mamma surgery, regional infiltration with ropivacaine 0,75% added to general anaesthesia causes less postoperative pain, nausea and vomiting compared to general anaesthesia alone.
The purpose of the present study is to obtain a pharmacokinetic profile of ropivacaine in serum with epinephrine, and of ropivacaine in serum without epinephrine, used for high dosed combined femoral and sciatic nerve block in lower extremity…
Het bestuderen en vergelijken van cocaïne, tetracaïne-oxymetazoline en ropivacaïne-oxymetazoline wat betreft de peroperatieve decongestie en hemostasis en postoperatieve analgesie die zij bieden bij FESS. Study and compare the peroperative…
to compare the analgesic efficacy of levobupivacaine and ropivacaine in patient-controlled epidural analgesia, as assessed by the number of requests for epidural bolus injectionsto compare visual analogue scale (VAS) scores and neural block…
To investigate if:-Kiovig is at least as effective as Gammagard. (equivalence)-Kiovig has a good side effect profile for CIDP patients.-Whether patients prefer Kiovig to Gammagard.
Reducing postoperative pain and nausea improves patient satisfaction.
The researchquestions of this study are:1. What is the efficacy of treatment of postoperative pain after subacromial decompression with a subacromial catheter with ropivacaine versus placebo?2. What are the differences in costs per patient and in…
The primary objective is to determine whether subjects with CIDP are overtreated with maintenance IVIg treatment and to reduce overtreatment-associated subjects* burden and health care costs.
Primary ObjectiveThe primary objective of this study is to evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of PFS in subjects with newly diagnosed MCL who are 65 years of age or older.Secondary…